

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **CHANGE OF DIRECTORS**

The Board hereby announces that, with effect from June 30, 2024:

- (1) Mr. XIA Yu (Ph.D.) has resigned as an executive Director;
- (2) Dr. ZHOU Yi has resigned as a non-executive Director; and
- (3) Dr. ZHANG Peng has been appointed as an executive Director.

### **RESIGNATION OF EXECUTIVE DIRECTOR AND NON-EXECUTIVE DIRECTOR**

The board (the “**Board**”) of directors (the “**Director(s)**”) of Akeso, Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) hereby announces that with effect from June 30, 2024, Mr. XIA Yu (Ph.D.) (“**Mr. XIA**”) has resigned as an executive Director and Dr. ZHOU Yi (“**Dr. ZHOU**”) has resigned as a non-executive Director in order to devote more time to their other work commitments.

Each of Mr. XIA and Dr. ZHOU has confirmed that he has no disagreement with the Board and there is no matter in relation to his resignation that needs to be brought to the attention of the shareholders of the Company or The Stock Exchange of Hong Kong Limited.

The Board would like to express its sincere gratitude to Mr. XIA and Dr. ZHOU for their valuable contribution to the Group during their tenure of office.

### **APPOINTMENT OF EXECUTIVE DIRECTOR**

The Board is pleased to announce that with effect from June 30, 2024, Dr. ZHANG Peng (“**Dr. ZHANG**”) has been appointed as an executive Director. The biographical details of Dr. ZHANG are set out below.

Dr. ZHANG, aged 48, is a co-founder of the Group. He has been a vice president of the Group since April 2012, and is currently the senior vice president of the Company. Dr. ZHANG is mainly responsible for corporate operations and government affairs of the Group. Dr. ZHANG has served as a vice president of Akeso Biopharma Co., Ltd.\* (中山康方生物醫藥有限公司) since early 2012. He has been a director of AD Pharmaceuticals Co., Ltd.\* (康融東方(廣東)醫藥有限公司) since February 2017, and a director of Akeso Pharma Co., Ltd.\* (康方藥業有限公司) since November 2018. Dr. ZHANG has approximately 20 years of experience in the therapeutic biologics industry.

Prior to commencing his career in the Group, Dr. ZHANG served as a teaching assistant in the Chemistry department of the University of Louisville in the U.S. from August 2001 to July 2002. From August 2002 to February 2007, he served as a teaching assistant in the Chemistry department of the University of Kentucky in the U.S. Dr. ZHANG served as a scientist in PDL BioPharma, Inc. from February 2007 to May 2008 and then as a senior director of the protein chemical department of Crown Bioscience Inc. from September 2008 to April 2012. In addition, since June 2010, he also served as the senior director and deputy general manager of Taicang CrownBio Analysis and Testing Company, Limited (中美冠科生物技術(太倉)有限公司), where he was primarily responsible for general management, business development and project management.

Dr. ZHANG obtained his bachelor's degree in chemistry and master's degree in analytical chemistry from Shandong University (山東大學) in the PRC in July 1998 and June 2001, respectively. Dr. ZHANG subsequently obtained his Ph.D. in chemistry from the University of Kentucky in the U.S. in May 2007.

Dr. ZHANG was selected as a member of The Pearl River Talent Program (珠江人才計劃) in April 2018, and recognized as a level three talent of the Shortage of High Level Talents of Zhongshan (中山市第三層次緊缺適用高層次人才) in February 2020. Dr. ZHANG was awarded the Most Beautiful Constructor in Zhongshan 2022 (2022年度中山最美建設者) in March 2023, and the Guangdong Province May 1st Labor Medal (廣東省五一勞動獎章) in April 2023. Dr. ZHANG was selected as one of the first directors of the Zhongshan New Social Class Federation (中山市新的社會階層人士聯合會) in July 2018.

Dr. ZHANG has entered into a service contract with the Company in relation to his appointment as an executive Director for an initial term of three years commencing from June 30, 2024. Dr. ZHANG will not receive any remuneration for serving as an executive Director. Dr. ZHANG shall hold office until the first annual general meeting of the Company after his appointment and shall then be eligible for re-election at that meeting. Dr. ZHANG is subject to retirement by rotation and re-election at the general meetings of the Company in accordance with the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the memorandum and articles of association of the Company.

As at the date of this announcement, Dr. ZHANG is deemed to be interested in 33,258,065 shares of the Company held by Waterband Limited. Waterband Limited is wholly-owned by Woodband Limited which in turn is beneficially owned by Woodband Trust. Woodband Trust was established by Dr. ZHANG as settlor with Cantrust (Far East) Limited as trustee.

As at the date of this announcement, save as disclosed above, Dr. ZHANG (i) does not have any relationship with any other Directors, senior management, substantial shareholders or controlling shareholders (as defined in the Listing Rules) of the Company; (ii) does not hold any other position within the Group; (iii) has not held any other directorships in any public companies in the last three years; (iv) is not interested or deemed to be interested in the shares, underlying shares or debentures of the Company or any of its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); and (v) there is no other information which is required to be disclosed pursuant to Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules nor any other matters that need to be brought to the attention of the shareholders of the Company in relation to his appointment.

The Board would like to take this opportunity to welcome Dr. ZHANG to join the Board.

By order of the Board  
**Akeso, Inc.**  
**Dr. XIA Yu**  
*Chairwoman and executive director*

Hong Kong, July 1, 2024

*As at the date of this announcement, the Board comprises Dr. XIA Yu as chairwoman and executive director, Dr. LI Baiyong, Dr. WANG Zhongmin Maxwell and Dr. ZHANG Peng as executive directors, Mr. XIE Ronggang as non-executive director, and Dr. ZENG Junwen, Dr. XU Yan and Mr. TAN Bo as independent non-executive directors.*

\* *For identification purpose only*